Zacks Rating on NuVasive (NUVA)

NuVasive (NUVA) : 12 brokerage houses believe that NuVasive (NUVA) is a Strong Buy at current levels. 2 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on NuVasive (NUVA). Zacks Investment Research suggests a Buy with a rank of 2.The median of all the 14 Wall Street Analysts endorse the stock as a Strong Buy with a rating of 1.29.

NuVasive (NUVA) : Average target price received by NuVasive (NUVA) is $67.18 with an expected standard deviation of $6.21. The most aggressive target on the stock is $77, whereas the most downbeat target is $58. 11 financial analysts are currently covering the stock.


Shares of NuVasive, Inc. rose by 1.26% in the last five trading days and 3.34% for the last 4 weeks. NuVasive, Inc. is up 18.37% in the last 3-month period. Year-to-Date the stock performance stands at 18.46%. NuVasive (NASDAQ:NUVA): stock turned positive on Tuesday. Though the stock opened at $63.8, the bulls momentum made the stock top out at $65 level for the day. The stock recorded a low of $63.8 and closed the trading day at $64.1, in the green by 0.93%. The total traded volume for the day was 391,621. The stock had closed at $63.51 in the previous days trading.

Nuvasive, Inc. is a global medical device company in the spine market. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine. Its marketed product portfolio is focused on applications for spine fusion surgery. Its product offering includes a minimally-disruptive surgical platform called Maximum Access Surgery (MAS). The MAS platform combines three categories of solutions that collectively minimize soft tissue disruption during spine fusion surgery, provide visualization and are designed to enable reproducible outcomes for the surgeon and the patient. The platform includes the Companys software-driven nerve detection and avoidance systems, including NVM5 and NVJJB, Intra-Operative Monitoring (IOM) services and support; MaXcess, which is an integrated split-blade retractor system, and a variety of implants and biologics.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.